2,6-Dimethoxyoxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,6-Dimethoxyoxane-3,4,5-triol
• 化学式: C₇H₁₄O₆
• 分子量: 194.18
• InChiKey: GNBDJKZVRKEPFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  88.4
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150104407A1

  公开（公告）日：2015-04-16

  A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

  本文描述了一种用于与基于蛋白质的识别分子（PBRM）共轭的聚合支架，形成PBRM-聚合物-药物共轭物的聚合支架。该支架包括一个或多个末端马来酰亚胺基团。还披露了从该支架制备的PBRM-聚合物-药物共轭物。还描述了包含这些共轭物的组合物、它们的制备方法以及使用这些共轭物或它们的组合物治疗各种疾病的方法。
• PHARMACEUTICAL COMPOSITION FOR ENZYME REPLACEMENT THERAPY
  申请人：Sakuraba Hitoshi

  公开号：US20100291059A1

  公开（公告）日：2010-11-18

  The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase.